Alveda Pharmaceuticals Inc.

Belkins
Responsible for the overall day-to-day operations. Responsible for the smooth operation of the process of producing and distributing the company's goods or of providing its services.

Related News

NATIONAL HEALTHCAREER ASSOCIATION (NHA) LAUNCHES COALITION FOR THE ADVANCEMENT OF PHARMACY TECHNICIAN PRACTICE

Prnewswire | August 20, 2020

news image

The National Healthcareer Association (NHA) has formed a unique, nationwide Pharmacy Technician Coalition. The coalition is focused solely on bringing pharmacy technician organizations, industry leaders, and associations together to advocate for and implement changes to expand the role of certified pharmacy technicians (CPhT), allowing them to help with needs during COVID-19. As pharmacies continue to provide more direct patient care services and are faced with increased workload during the pand...

Read More

THERMO FISHER SCIENTIFIC LAUNCHES MODULAR CLOSED CELL PROCESSING SYSTEM FOR CELL THERAPY MANUFACTURING

Thermo Fisher | October 15, 2020

news image

Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The CTS Rotea system is the first Gibco instrument for cell therapy processing applications and facilitates workflows from research through GMP clinical development and commercial manufacturing. As of mid-2020, 675 clinical trials were underway globally for cell th...

Read More

RESEARCH

ALGERNON PHARMACEUTICALS SIGNS AGREEMENT WITH CHARLES RIVER LABORATORIES FOR DMT PRECLINICAL STUDIES

Algernon Pharmaceuticals, Charles River Laboratories | February 11, 2021

news image

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that is has signed an agreement with Charles River Laboratories for preclinical studies of AP-188 ("N,N-Dimethyltryptamine or DMT") for the Company's stroke clinical research program. Algernon's preclinical study of DMT will be conducted at the Charles River research facility in Finland. Charles River Laboratories, Inc. is an American corporation specializing ...

Read More

PHARMACY MARKET

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

news image

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More
news image

NATIONAL HEALTHCAREER ASSOCIATION (NHA) LAUNCHES COALITION FOR THE ADVANCEMENT OF PHARMACY TECHNICIAN PRACTICE

Prnewswire | August 20, 2020

The National Healthcareer Association (NHA) has formed a unique, nationwide Pharmacy Technician Coalition. The coalition is focused solely on bringing pharmacy technician organizations, industry leaders, and associations together to advocate for and implement changes to expand the role of certified pharmacy technicians (CPhT), allowing them to help with needs during COVID-19. As pharmacies continue to provide more direct patient care services and are faced with increased workload during the pand...

Read More
news image

THERMO FISHER SCIENTIFIC LAUNCHES MODULAR CLOSED CELL PROCESSING SYSTEM FOR CELL THERAPY MANUFACTURING

Thermo Fisher | October 15, 2020

Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The CTS Rotea system is the first Gibco instrument for cell therapy processing applications and facilitates workflows from research through GMP clinical development and commercial manufacturing. As of mid-2020, 675 clinical trials were underway globally for cell th...

Read More
news image

RESEARCH

ALGERNON PHARMACEUTICALS SIGNS AGREEMENT WITH CHARLES RIVER LABORATORIES FOR DMT PRECLINICAL STUDIES

Algernon Pharmaceuticals, Charles River Laboratories | February 11, 2021

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that is has signed an agreement with Charles River Laboratories for preclinical studies of AP-188 ("N,N-Dimethyltryptamine or DMT") for the Company's stroke clinical research program. Algernon's preclinical study of DMT will be conducted at the Charles River research facility in Finland. Charles River Laboratories, Inc. is an American corporation specializing ...

Read More
news image

PHARMACY MARKET

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More